Principal – Novartis Venture Funds
Dr. Beat Steffen is a Principal at NVF in Basel, Switzerland. Prior to joining NVF, he worked at Novartis Pharmaceuticals in commercial roles in the US and in Switzerland launching several products mainly in the cardiovascular area.
Beat joined Novartis from Wellington Partners Venture Capital where he worked with biotech and medical device startup companies.
Prior to that, he was at McKinsey & Company in Zurich working with clients in the pharmaceutical industry. Beat is a Swiss-trained physician having focused in cardiovascular surgery and intensive care. He graduated from the University of Zurich Medical School and qualified as a Medical Doctor in Basel. Beat holds an MBA with distinction from INSEAD.
Head Roche Venture Fund
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.
She currently serves as a director at CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Inc., Millendo Therapeutics, Mission Therapeutics, Second Genome, Tioma Therapeutics and Vivet Therapeutics and as board observer on Allakos, C4 and Maculogix. Carole also led the investments on Alios, Ambit, AveXis, Conatus, Envoy & Pharmasset. She has a BA from Valparaiso University and a JD from University of Michigan.
More information on the Roche Roche Venture Fund can be found at www.venturefund.roche.com
Vice President of Worldwide Business Development - Pfizer Inc.
Dr. Monika Vnuk is Vice President of Worldwide Business Development for Pfizer Inc. In this role, Dr. Vnuk leads an international team responsible for executing all pre-clinical business development transactions for Pfizer.
Before joining Pfizer, Dr. Vnuk was a Vice President at Banc of America Securities. Prior to her position at Banc of America, Dr. Vnuk was a Principal at Oxford Bioscience Partners, a venture capital firm focused on early stage biotechnology investments.
Dr. Vnuk is serves on the Board of Trustees of BioNJ, a non-for-profit organization representing the interests of life sciences companies in the state of New Jersey.
Dr. Vnuk is a 2000 Inductee to the Alpha Omega Alpha Medical Honor Society. Dr. Vnuk holds a B.A. in Mathematics and Philosophy from Boston University and an M.D. from Boston University School of Medicine.
Partner - HealthCap
Dr. Mårten Steen. Partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology licensing. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.
Founder and Managing Partner of Columbus Venture Partners
Founder and Managing Partner of Columbus Venture Partners S.G.E.I.C., S.A
Javier Garcia has spent almost 30 years working in healthcare and the biopharmaceutical industry. He spent 25 years at Eli Lilly and Company. He hold senior management positions in Business Development and Information Technology. Currently he serves on the Board of Askbio, Viralgen Vector Core, Artax Biopharma, and Bioncotech Therapeutics. He is also a board member for the National Alliance for Hispanic Health and the Healthy Americas Foundation both NFP organizations in Washington DC.
Mr. Garcia received a Bachelor in Mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and a MBA from ICADE (Spain).
Managing Partner - Kurma
Scientist by training, Vanessa started joined the Paris based VC fund CDC-Innovation in 1998 as an analyst, prior to joining a California based start up to be in charge of the business development activities. Vanessa then joined Ipsen in 2003, as Strategic Advisor to the CEO and headed the portfolio management team for the gastro-enterology product range (totaling more than 130M€). Vanessa was appointed in 2005 as Product Manager and Team Leader for febuxostat (Adenuric), which received EMA approval in 2008. Vanessa was then successively appointed as Senior Director, Business Development Oncology in 2009 and VP, R&D Strategic Planning in 2011. Vanessa graduated in Biology at Ecole Normale Superieure, Cachan and in Immunology at Pasteur Institute. Vanessa joined Kurma in September 2013 and is responsible for the investment in Xeltis (Switzerland), Asceneuron (Switzerland), Step Pharam (France) and Vivet Therapeutics (France).
General Partner - Ysios Capital
Karen Wagner is a Managing Partner at Ysios Capital where she focuses on therapeutic investments. She joined the firm at its inception in 2008. Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare companies, with an exclusive focus on therapeutics and close to € 200 million under management.
Besides Vivet Therapeutics, Karen serves on the boards of Galecto, Aelix Therapeutics, Minoryx and Xeltis. Formerly she was a board member of Kala Pharmaceutics and Cardoz. Karen has over 20 years of experience in business development and financing in the biotech/pharma sector working for companies such as F. Hoffmann-La Roche and GlycArt. Previously she was a Consultant with McKinsey & Company’s Global Healthcare Practice.
She holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.
Idinvest Partners is a leading European mid-market private equity firm. With close to €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market corporate debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997 Idinvest Partners used to be an Allianz subsidiary until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners joined forces with Eurazeo to create a private equity leader in Europe and North America with €15bn under management.